MAY 24, 2018 09:00 AM PDT
Dissecting the Tumor Microenvironment Part 1 - Tools for Isolation and Flow Analysis
SPONSORED BY: Miltenyi Biotec
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
7 30 4646

Speakers:
  • Manager of R&D Oncology, Miltenyi Biotec
    Biography
      Dr. Olaf Hardt obtained his Ph.D. at the University of Cologne, Germany in collaboration with Miltenyi Biotec and the IBDML in Marseille, France before he started as R&D Project Manager at Miltenyi Biotec in 2008. In his current position as Manager R&D Oncology for Miltenyi Biotec in Bergisch Gladbach, Germany, he focuses on immuno-oncology preclinical research, target discovery, as well as oncology related product development. He also heads the transgenic unit and animal facility.

    Abstract:

    DATE: May 24, 2018
    TIME: 9:00AM PDT, 5:00PM CET

    Isolation of tumor cells and tumor-infiltrating leukocytes for optimized downstream analysis

    Recent advances in immuno-oncology research have proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells within the tumor microenvironment is key to developing future immune based cancer therapy strategies. However, the most significant challenge to working with solid tumors is the need to dissociate the samples prior to their use in downstream applications, such as immunomagnetic enrichment, flow cytometry, and single-cell sequencing. Furthermore, tumor cells can cause background signals and introduce bias to the analysis of immune cells.

    Learning Objectives:

    •    Optimized and automated dissociation of tumor tissue resulting in high yield, viability, and improved cell surface marker detection

    •    Analysis of tumor cells by flow cytometry

    •    Isolation of tumor subpopulations for enhancing NGS based analyses

    •    Isolation and analysis of tumor-infiltrating immune cell subpopulations (TILs)

     

     

     

     

     

     

     

     


    Show Resources
    Loading Comments...